Scientific, peer-reviewed, clinical
publications about Tris Pharma products

Publications

Click on any title below to read the full article or abstract.

Amphetamine Extended-Release Tablet

Randomized, double-blind, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of amphetamine extended-release tablets in adults with attention-deficit/hyperactivity disorder. Cutler AJ, Childress AC, Pardo A, et al. J Clin Psychiatry. 2022;83(5):22m14438.

Assessing palatability of a new amphetamine extended-release tablet formulation for the treatment of ADHD. Pardo A, King TR, Rafla E, Kando JC. Drug Des Devel Ther. 2021;15:2979–2985.

Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension. Pardo A, Kando JC, King TR, Rafla E, Herman BK. CNS Spectr. 2020;22:1-8.

Amphetamine Extended-Release Oral Suspension

Single-dose pharmacokinetics of amphetamine extended-release oral suspension in healthy adults. Herman BK, Bouhajib M, King TR, Kando JC, Pardo A. J Atten Disord. 2021;25(6):803-808. doi: 10.1177/1087054719841131.

Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension. Pardo A, Kando JC, King TR, Rafla E, Herman BK. CNS Spectr. 2020;22:1-8.

Early-onset efficacy and safety pilot study of amphetamine extended-release oral suspension in the treatment of children with attention-deficit/hyperactivity disorder. Childress AC, Kando JC, King TR, Pardo A, Herman BK. J Child Adolesc Psychopharmacol. 2019;29(1):2-8.

Efficacy and safety of amphetamine extended-release oral suspension in children with attention-deficit/hyperactivity disorder. Childress AC, Wigal SB, Brams MN, et al. J Child Adolesc Psychopharmacol. 2018;28(5):306-313.

Methylphenidate Extended-Release Tablet

Relative bioavailability of methylphenidate extended-release chewable tablets chewed versus swallowed whole. Abbas R, Childress AC, Nagraj B, et al. Clin Ther. 2018;40(5):733-740.

Optimization of methylphenidate extended-release chewable tablet dose in children with ADHD: open-label dose optimization in a laboratory classroom study. Wigal SB, Childress A, Berry SA, et al. J Child Adolesc Psychopharmacol. 2018;28(5):314-321.

Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention deficit/hyperactivity disorder. Wigal SB, Childress AC, Berry SA, et al. J Child Adolesc Psychopharmacol. 2017;27(8):690-699.

Single-dose pharmacokinetic properties and relative bioavailability of a novel methylphenidate extended-release chewable tablet compared with immediate-release methylphenidate chewable tablet. Abbas R, Palumbo D, Walters F, Belden H, Berry SA. Clin Ther. 2016;38(5):1151-1157.

Methylphenidate Extended-Release Oral Suspension

Efficacy, safety, and tolerability of a novel methylphenidate extended-release oral suspension (MEROS) in ADHD. Robb AS, Findling RL, Childress AC, Berry SA, Belden HW, Wigal SB. J Atten Disord. 2017;21(14):1180-1191.

Effect of food intake on the pharmacokinetics of a novel methylphenidate extended-release oral suspension for attention deficit hyperactivity disorder. Sallee FR, Palumbo DR, Abbas R, Berry SA, Puthili SP, Kathala KK. Clin Pharmacol Drug Dev. 2017;6(5):476-483.

NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. Wigal SB, Childress AC, Belden HW, Berry SA. J Child Adolesc Psychopharmacol. 2013;23(1):3-10.

Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. Childress AC, Sallee FR, Berry SA. Postgrad Med. 2011;123(5):80-88.

The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Childress AC, Berry SA. Postgrad Med. 2010;122(5):35-41.